Oncology Institute (TOI) holder discloses 5.2% ownership stake filing

Rhea-AI Filing Summary

Oncology Institute, Inc. reported that investor Jorey Chernett has filed a Schedule 13G disclosing a significant ownership position in the company’s common stock. Chernett beneficially owns 5,114,944 shares of common stock, representing 5.2% of the class. All of these shares are reported with sole voting and sole dispositive power, with no shared voting or dispositive authority.

The filing indicates this is a passive investment. Chernett certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of Oncology Institute, Inc., and are not held in connection with any transaction intended to have that effect. The date of the ownership event triggering the filing is stated as January 14, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Oncology Institute, Inc.

(Name of Issuer)

Common

(Title of Class of Securities)

23343Q100

(CUSIP Number)

01/14/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23343Q100

1

Names of Reporting Persons

Chernett Jorey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,114,944.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,114,944.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,114,944.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Oncology Institute, Inc.
(b)	Address of issuer's principal executive offices: 18000 Studebaker Rd., Ste. 800, Cerritos, CALIFORNIA, 90703.
Item 2.
(a)	Name of person filing: Jorey Chernett
(b)	Address or principal business office or, if none, residence: 6222 Indianwood Trail, Bloomfield Hills, MI 48301
(c)	Citizenship: US
(d)	Title of class of securities: Common
(e)	CUSIP No.: 23343Q100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,114,944
(b)	Percent of class: 5.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5,114,944
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5,114,944
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chernett Jorey

Signature:	/s/Jorey Chernett
Name/Title:	Individual
Date:	01/15/2026

FAQ

Who filed the Schedule 13G for Oncology Institute, Inc. (TOI)?

The Schedule 13G was filed by Jorey Chernett as the reporting person and beneficial owner of a significant stake in Oncology Institute, Inc.

How many Oncology Institute, Inc. (TOI) shares does Jorey Chernett beneficially own?

Jorey Chernett beneficially owns 5,114,944 shares of Oncology Institute, Inc. common stock, according to the Schedule 13G.

What percentage of Oncology Institute, Inc. (TOI) is owned by Jorey Chernett?

The filing reports that Jorey Chernett’s 5,114,944 shares represent 5.2% of the outstanding common stock of Oncology Institute, Inc.

Does Jorey Chernett have sole or shared voting power over TOI shares?

The Schedule 13G states that Jorey Chernett has sole voting power and sole dispositive power over all 5,114,944 shares, with no shared voting or dispositive power.

Is the Oncology Institute, Inc. (TOI) stake held for control purposes?

No. Chernett certifies that the TOI shares were not acquired and are not held for the purpose of changing or influencing control of Oncology Institute, Inc.

When did the ownership event requiring this TOI Schedule 13G occur?

The date of the event that required this Schedule 13G filing is listed as January 14, 2026.

Is Jorey Chernett part of a group holding Oncology Institute, Inc. (TOI) shares?

No. The Schedule 13G indicates the ownership is reported individually, and the items on group membership and group dissolution are marked Not Applicable.